Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Rhea-AI Summary

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, announced its participation in the upcoming Leerink Partners Therapeutics Forum focused on I&I and Metabolism. The event will be held from July 8-9 in Boston, Massachusetts. The company's senior management, including President and CEO Jennifer Good and CFO Lisa Delfini, will be in attendance.

Trevi is currently developing Haduvio™ (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

News Market Reaction – TRVI

+4.20%

1 alert

+4.20% News Effect

On the day this news was published, TRVI gained 4.20%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts.

About Trevi Therapeutics, Inc.    
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC.  Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. 

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact 
Katie Barrett 
Trevi Therapeutics, Inc. 
(203) 903 9627 
k.barrett@trevitherapeutics.com

Media Contact 
Rosalia Scampoli 
914-815-1465 
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-attend-leerink-partners-therapeutics-forum-ii-and-metabolism-302494927.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When is Trevi Therapeutics (TRVI) presenting at the Leerink Partners Therapeutics Forum?

The Leerink Partners Therapeutics Forum will be held from July 8-9, 2025 in Boston, Massachusetts.

Who will represent Trevi Therapeutics (TRVI) at the Leerink Partners conference?

Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will attend the conference.

What is Trevi Therapeutics (TRVI) developing Haduvio for?

Haduvio (oral nalbuphine ER) is being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Where is the Leerink Partners Therapeutics Forum being held?

The forum will be held in Boston, Massachusetts.